AI English summary of an SEC filing — figures as filed
Fortive FTVThe company said that on February 26, 2025, it increased the size of its board from 9 to 10 members and appointed Gregory J. Moore, M.D., Ph.D., as a director.
Key points
AI summaryThe company said that on February 26, 2025, it increased the size of its board from 9 to 10 members and appointed Gregory J. Moore, M.D., Ph.D., as a director.
Fortive said Dr. Moore's term begins on February 26, 2025 and expires at the 2025 Annual Meeting of Shareholders. The company also appointed him to the Compensation Committee and Nominating and Governance Committee at the same time.
Fortive said Dr. Moore, as a non-employee director, receives the same compensation as the Company's other non-employee directors. It added that he has entered into an indemnification agreement with the company.
The company said its board determined that Dr. Moore is independent under New York Stock Exchange listing standards. It said there is no arrangement or understanding with any other person regarding his selection and no transactions requiring disclosure under Item 404(a).
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Fortive Expands Board and Appoints New Director
The company said that on February 26, 2025, it increased the size of its board from 9 to 10 members and appointed Gregory J. Moore, M.D., Ph.D., as a director.
Source · Based on the filing body and exhibits
New Director's Term and Committee Assignments
Fortive said Dr. Moore's term begins on February 26, 2025 and expires at the 2025 Annual Meeting of Shareholders. The company also appointed him to the Compensation Committee and Nominating and Governance Committee at the same time.
Source · Based on the filing body and exhibits
Non-Employee Director Compensation and Indemnification
Fortive said Dr. Moore, as a non-employee director, receives the same compensation as the Company's other non-employee directors. It added that he has entered into an indemnification agreement with the company.
Source · Based on the filing body and exhibits
Independence Determination and No Related Interests
The company said its board determined that Dr. Moore is independent under New York Stock Exchange listing standards. It said there is no arrangement or understanding with any other person regarding his selection and no transactions requiring disclosure under Item 404(a).
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…